Novartis Investigative Site

Münster, Germany 48149

0 studies enrolling now · 1 studies all time

What they study most

Moderate to Severe Plaque-type Psoriasis

Studies at this site

• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed